RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.

@article{Wolf2014RADIANCEAR,
  title={RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.},
  author={Sebastian Wolf and Vilma Jurate Balciuniene and Guna Laganovska and Ugo Menchini and Kyoko Ohno-Matsui and Tarun Sharma and Tien Yin Wong and Rufino Silva and Stefan Pilz and Margarita Gekkieva},
  journal={Ophthalmology},
  year={2014},
  volume={121 3},
  pages={682-92.e2}
}
OBJECTIVE To compare the efficacy and safety of ranibizumab 0.5 mg, guided by visual acuity (VA) stabilization or disease activity criteria, versus verteporfin photodynamic therapy (vPDT) in patients with visual impairment due to myopic choroidal neovascularization (CNV). DESIGN Phase III, 12-month, randomized, double-masked, multicenter, active-controlled study. PARTICIPANTS Patients (N = 277) with visual impairment due to myopic CNV. METHODS Patients were randomized to receive… CONTINUE READING
54 Citations
45 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Summary of Product Characteristics . Lucentis 10 mg / ml solution for injection . Novartis

  • JM Ruiz-Moreno, JA Montero, S Gomez-UllaAres
  • 2013

Similar Papers

Loading similar papers…